NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Abdera Therapeutics

Abdera Therapeutics

Private
VancouverHealthcare & Life Scienceshttps://abderatx.com/

Last Round

Series B

Apr 4, 2023

Total Funding Raised

$180.78M

Company Overview

Abdera Therapeutics is a biotechnology company that develops a precision oncology platform for targeted alpha radiation therapies aimed at patients with relapsed, refractory, and metastatic cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

radiopharmaceutical therapytargeted cancer therapyoncologyantibody engineeringsmall cell lung cancertheranosticsradionuclide therapyprecision medicinedrug discoveryclinical trialsbiotechneuroendocrine tumorspharmacokineticsdosimetrydrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abdera Therapeutics Comparables

Compare Abdera Therapeutics with similar companies based on industry and business-model similarity.

Abdera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alpha-9 Oncology
87%
Radionetics Oncology
87%
Ratio Therapeutics Inc.
84%

Abdera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 4, 2023
SeedJan 14, 2021

Key People

Founding team and executive leadership

Lana Janes

Co-Founder And Senior Vice President, Operations And Innovation, Chief Operating Officer

Founding Team

Abdera Therapeutics Investors

Notable investors and investment history

Abdera Therapeutics investors
InvestorRounds
Amplitude VenturesSeries B, Series A
Versant VenturesSeries B, Series A
Viking Global InvestorsSeries B
venBioSeries B
QimingSeries B
Northview LifeSciencesSeries A, Series B
RTW InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 13, 2026

    Presenting at the 44th Annual J.P. Morgan Healthcare Conference.

  • Aug 26, 2025

    Initial Phase 1 data for ABD-147 presented at IASLC 2025.

Abdera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Abdera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Abdera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver
Employee Range43
Year Founded2020
Last FundingApr 4, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.